CorMedix announces dosing of premier acquiescent with CRMD-001 in Put a stop to II clinical stab
CorMedix Inc. ("CorMedix") (NYSE Amex: CRMD), a pharmaceutical followers focused on developing and commercializing healthy products fit the checking and treatment of Cardiorenal infirmity, today announced dosing of the primary sedulous with CRMD-001 (a proprietary formulation of deferiprone) in a randomized, double-blind, placebo-controlled clinical hassle. This Moment II proof-of-concept investigate is as a service to the debarment of contrast-induced sharp kidney wound in around 60 high-risk patients with persistent kidney ailment (CKD) and additional jeopardy factors, who are undergoing coronary angiography with the purpose of adjunctive percutaneous coronary intervention (PCI). This examine is currently being conducted at two examine centers in the Of like mind States: Far-sightedness Asylum and Medical Center in Southfield, MI and Northern Michigan Regional Polyclinic in Petoskey, MI.
“There may be a consequential shot as a remedy for CRMD-001 to fulfill the unmet medical call of preventing contrast-induced nephropathy in high-risk patients, and we look help to generating compelling clinical data”
The exceptional aspiration of this experiment is to assess the modify of the verbal iron chelator, CRMD-001 on reactive biomarkers of contrast-induced violent kidney maltreatment in this high-risk diligent denizens with CKD. In beyond, the library will-power assess the security and tolerability of CRMD-001 in compensation short-term press into service. Patients transfer be randomized to be paid either CRMD-001 or placebo, and they bequeath be dosed orally in the service of 8 days, starting right now previously to to coronary angiography. Biomarker, safe keeping and clinical endpoints make be assessed wholly 90 days.
"There may be a weighty crack in requital for CRMD-001 to fulfill the unmet medical needfulness of preventing contrast-induced nephropathy in high-risk patients, and we look fresh to generating compelling clinical facts," stated Peter A. McCullough, MD, MPH, Hero Investigator of the bone up on.
"The collective demonstration by reason of the character of labile iron in kidney and courage diseases is to some formidable. Based upon deferiprone’s well-characterized efficacy in reducing dissoluteness labile iron, we have faith it when one pleases state look after charge against contrast-induced keen kidney offence and associated cardiovascular complications," commented Sudhir V. Shah, MD, FACP, colleague of CorMedix’s thorough admonition plank.
FOUNTAIN-HEAD CorMedix Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
